A Phase 3 interventional study of 13vPnC and PPSV23 in Pneumococcal Disease, sponsored by Pfizer. Completed at 42 sites in 2 countries. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-02-21.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 8th largest by enrollment, is one of 2 that started in 2019, is one of 14 in phase 3, and was the 3rd registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 65 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 2 started in 2019.
This study's enrollment of 875 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 22nd largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2019, is one of 33 in phase 3, and was the 48th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
This Phase 3 will describe the safety and immunogenicity of a 20-valent pneumococcal conjugate vaccine formulation in adults 65 years of age or older with prior pneumococcal vaccination
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female adults who meet 1 of the following:
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pneumococcal conjugate vaccine
Biological: 13vPnC
Pneumococcal polysaccharide vaccine
Biological: PPSV23
Pneumococcal conjugate vaccine
Biological: 20vPnC
Pneumococcal conjugate vaccine
Drug page: 23-valent pneumococcal capsular polysaccharide vaccine
Pneumococcal polysaccharide vaccine
Pneumococcal conjugate vaccine
Percentage of Participants With Local Reactions Within 10 Days After Vaccination
Local reactions were recorded using an electronic diary (e-diary). Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
Time frame: Within 10 days after vaccination
Percentage of Participants With Systemic Events Within 7 Days After Vaccination
Systemic events fever, fatigue, headache, muscle pain and joint pain were recorded by using an e-diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity).
Time frame: Within 7 days after vaccination
Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination
An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship with the treatment.
Time frame: Within 1 month after vaccination
Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination
An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event.
Time frame: Within 6 months after vaccination
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects.
Time frame: Within 6 months after vaccination
Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) at 1 Month After Vaccination
OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution.
Time frame: 1 month after vaccination
Pneumococcal OPA Geometric Mean Fold Rise (GMFR) From Before Vaccination to 1 Month After Vaccination
OPA GMFR is the ratio of OPA GMTs, 1 month after vaccination to before vaccination. OPA GMFRs from before to 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
Time frame: From before vaccination to 1 month after vaccination
Percentage of Participants With >=4-Fold Rise in Pneumococcal OPA Titers From Before Vaccination to 1 Month After Vaccination
Percentage of participants with a \>=4-fold rise in pneumococcal OPA titers from before vaccination to 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
Time frame: From before vaccination to 1 month after vaccination
Percentage of Participants With Pneumococcal OPA Titers >=Lower Limit of Quantitation (LLOQ) at 1 Month After Vaccination
The percentage of participants with OPA titers \>=LLOQ at 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
Time frame: 1 month after vaccination
| Milestone | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC |
|---|---|---|---|---|---|
| Started | 253 | 122 | 248 | 127 | 125 |
| Vaccinated | 253 | 122 | 246 | 127 | 125 |
| Safety population | 253 | 122 | 246 | 127 | 125 |
| Evaluable immunogenicity population (for 20vpnc cohorts) | 247 | 0 | 243 | 0 | 121 |
| Completed | 250 | 119 | 245 | 126 | 125 |
| Not completed | 3 | 3 | 3 | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 1 | 0 | 0 | 0 |
| Withdrew: No longer met eligibility criteria | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 1 | 1 | 0 |
Local reactions were recorded using an electronic diary (e-diary). Local reactions included redness, swelling and pain at the injection site. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 2.0 to 5.0 cm), moderate (\>5.0 to 10.0 cm) and severe (\>10.0 cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).
| percentage of participants | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC |
|---|---|---|---|---|---|
| Redness: Any | 7.9 (4.9 to 11.9) | 2.5 (0.5 to 7.1) | 8.6 (5.4 to 12.8) | 12.7 (7.4 to 19.8) | 4.8 (1.8 to 10.2) |
| Redness: Mild | 3.6 (1.6 to 6.6) | 1.7 (0.2 to 5.8) | 2.9 (1.2 to 5.8) | 4.8 (1.8 to 10.1) | 1.6 (0.2 to 5.7) |
| Redness: Moderate | 3.2 (1.4 to 6.1) | 0.8 (0.0 to 4.5) | 5.3 (2.9 to 8.9) | 7.1 (3.3 to 13.1) | 3.2 (0.9 to 8.0) |
| Redness: Severe | 1.2 (0.2 to 3.4) | 0 (0.0 to 3.0) | 0.4 (0.0 to 2.3) | 0.8 (0.0 to 4.3) | 0 (0.0 to 2.9) |
| Swelling: Any | 9.9 (6.5 to 14.2) | 6.6 (2.9 to 12.6) | 9.4 (6.0 to 13.8) | 14.3 (8.7 to 21.6) | 4.0 (1.3 to 9.1) |
| Swelling: Mild | 5.1 (2.8 to 8.6) | 6.6 (2.9 to 12.6) | 5.7 (3.2 to 9.4) | 6.3 (2.8 to 12.1) | 1.6 (0.2 to 5.7) |
| Swelling: Moderate | 3.6 (1.6 to 6.6) | 0 (0.0 to 3.0) | 3.7 (1.7 to 6.9) | 7.1 (3.3 to 13.1) | 2.4 (0.5 to 6.9) |
| Swelling: Severe | 1.2 (0.2 to 3.4) | 0 (0.0 to 3.0) | 0 (0.0 to 1.5) | 0.8 (0.0 to 4.3) | 0 (0.0 to 2.9) |
| Pain at the injection site: Any | 50.2 (43.9 to 56.5) | 43.0 (34.0 to 52.3) | 61.2 (54.8 to 67.4) | 56.3 (47.2 to 65.2) | 52.8 (43.7 to 61.8) |
| Pain at the injection site: Mild | 45.8 (39.6 to 52.2) | 38.8 (30.1 to 48.1) | 54.7 (48.2 to 61.0) | 40.5 (31.8 to 49.6) | 47.2 (38.2 to 56.3) |
| Pain at the injection site: Moderate | 4.3 (2.2 to 7.6) | 3.3 (0.9 to 8.2) | 6.1 (3.5 to 9.9) | 14.3 (8.7 to 21.6) | 5.6 (2.3 to 11.2) |
| Pain at the injection site: Severe | 0 (0.0 to 1.4) | 0.8 (0.0 to 4.5) | 0.4 (0.0 to 2.3) | 1.6 (0.2 to 5.6) | 0 (0.0 to 2.9) |
Systemic events fever, fatigue, headache, muscle pain and joint pain were recorded by using an e-diary. Fever was defined as temperature \>=38.0 degree Celsius (C) and categorized to \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0 degree C. Fatigue, headache, muscle pain and joint pain were graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily routine activity).
| percentage of participants | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC |
|---|---|---|---|---|---|
| Fever: >=38.0 degree C | 0.8 (0.1 to 2.8) | 0 (0.0 to 3.0) | 0 (0.0 to 1.5) | 1.6 (0.2 to 5.6) | 0 (0.0 to 2.9) |
| Fever: >=38.0 degree C to 38.4 degree C | 0.8 (0.1 to 2.8) | 0 (0.0 to 3.0) | 0 (0.0 to 1.5) | 0.8 (0.0 to 4.3) | 0 (0.0 to 2.9) |
| Fever: >38.4 degree C to 38.9 degree C | 0 (0.0 to 1.4) | 0 (0.0 to 3.0) | 0 (0.0 to 1.5) | 0.8 (0.0 to 4.3) | 0 (0.0 to 2.9) |
| Fever: >38.9 degree C to 40.0 degree C | 0 (0.0 to 1.4) | 0 (0.0 to 3.0) | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) | 0 (0.0 to 2.9) |
| Fever: >40.0 degree C | 0 (0.0 to 1.4) | 0 (0.0 to 3.0) | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) | 0 (0.0 to 2.9) |
| Fatigue: Any | 28.9 (23.4 to 34.9) | 22.3 (15.2 to 30.8) | 31.0 (25.3 to 37.2) | 33.3 (25.2 to 42.3) | 32.8 (24.7 to 41.8) |
| Fatigue: Mild | 17.8 (13.3 to 23.1) | 9.9 (5.2 to 16.7) | 19.6 (14.8 to 25.1) | 19.8 (13.3 to 27.9) | 19.2 (12.7 to 27.2) |
| Fatigue: Moderate | 11.1 (7.5 to 15.6) | 9.9 (5.2 to 16.7) | 10.2 (6.7 to 14.7) | 13.5 (8.1 to 20.7) | 12.0 (6.9 to 19.0) |
| Fatigue: Severe | 0 (0.0 to 1.4) | 2.5 (0.5 to 7.1) | 1.2 (0.3 to 3.5) | 0 (0.0 to 2.9) | 1.6 (0.2 to 5.7) |
| Headache: Any | 17.8 (13.3 to 23.1) | 18.2 (11.8 to 26.2) | 13.5 (9.5 to 18.4) | 21.4 (14.6 to 29.6) | 19.2 (12.7 to 27.2) |
| Headache: Mild | 12.6 (8.8 to 17.4) | 12.4 (7.1 to 19.6) | 9.8 (6.4 to 14.2) | 20.6 (13.9 to 28.8) | 12.8 (7.5 to 20.0) |
| Headache: Moderate | 4.7 (2.5 to 8.1) | 5.8 (2.4 to 11.6) | 3.7 (1.7 to 6.9) | 0.8 (0.0 to 4.3) | 5.6 (2.3 to 11.2) |
| Headache: Severe | 0.4 (0.0 to 2.2) | 0 (0.0 to 3.0) | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) | 0.8 (0.0 to 4.4) |
| Muscle Pain: Any | 32.0 (26.3 to 38.1) | 31.4 (23.3 to 40.5) | 33.9 (28.0 to 40.2) | 46.0 (37.1 to 55.1) | 37.6 (29.1 to 46.7) |
| Muscle Pain: Mild | 26.1 (20.8 to 32.0) | 24.0 (16.7 to 32.6) | 25.3 (20.0 to 31.2) | 31.7 (23.7 to 40.6) | 28.0 (20.3 to 36.7) |
| Muscle Pain: Moderate | 5.5 (3.1 to 9.1) | 5.0 (1.8 to 10.5) | 8.6 (5.4 to 12.8) | 11.9 (6.8 to 18.9) | 8.8 (4.5 to 15.2) |
| Muscle Pain: Severe | 0.4 (0.0 to 2.2) | 2.5 (0.5 to 7.1) | 0 (0.0 to 1.5) | 2.4 (0.5 to 6.8) | 0.8 (0.0 to 4.4) |
| Joint Pain: Any | 6.7 (4.0 to 10.5) | 10.7 (5.8 to 17.7) | 11.8 (8.1 to 16.6) | 15.9 (10.0 to 23.4) | 16.8 (10.7 to 24.5) |
| Joint Pain: Mild | 4.7 (2.5 to 8.1) | 5.0 (1.8 to 10.5) | 7.8 (4.7 to 11.8) | 10.3 (5.6 to 17.0) | 12.8 (7.5 to 20.0) |
| Joint Pain: Moderate | 2.0 (0.6 to 4.6) | 5.0 (1.8 to 10.5) | 4.1 (2.0 to 7.4) | 5.6 (2.3 to 11.1) | 4.0 (1.3 to 9.1) |
| Joint Pain: Severe | 0 (0.0 to 1.4) | 0.8 (0.0 to 4.5) | 0 (0.0 to 1.5) | 0 (0.0 to 2.9) | 0 (0.0 to 2.9) |
An AE was any untoward medical occurrence in study participants who received study vaccine without regard to possibility of causal relationship with the treatment.
| percentage of participants | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC |
|---|---|---|---|---|---|
| Percentage of Participants With Adverse Events (AEs) Within 1 Month After Vaccination | 7.5 (4.6 to 11.5) | 9.0 (4.6 to 15.6) | 4.9 (2.5 to 8.4) | 11.0 (6.2 to 17.8) | 10.4 (5.7 to 17.1) |
An SAE was any untoward medical occurrence at any dose that results in death; is life-threatening (immediate risk of death); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); results in congenital anomaly/birth defect or that is considered to be an important medical event.
| percentage of participants | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC |
|---|---|---|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) Within 6 Months After Vaccination | 0.8 (0.1 to 2.8) | 1.6 (0.2 to 5.8) | 2.4 (0.9 to 5.2) | 1.6 (0.2 to 5.6) | 1.6 (0.2 to 5.7) |
An NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects.
| percentage of participants | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC |
|---|---|---|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) Within 6 Months After Vaccination | 2.0 (0.6 to 4.6) | 0.8 (0.0 to 4.5) | 2.8 (1.2 to 5.8) | 2.4 (0.5 to 6.7) | 4.0 (1.3 to 9.1) |
OPA GMTs were determined for serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F. OPA titer was expressed as reciprocal of the highest serum dilution.
| titer | Cohort A: 20vPnC | Cohort B: 20vPnC | Cohort C: 20vPnC |
|---|---|---|---|
| Serotype 1 | 50.8 (41.6 to 62.0) | 115.3 (96.3 to 137.9) | 82.1 (61.2 to 110.1) |
| Serotype 3 | 31.1 (26.7 to 36.1) | 54.3 (46.9 to 62.8) | 39.3 (32.0 to 48.2) |
| Serotype 4 | 149.9 (118.2 to 190.1) | 334.9 (273.8 to 409.5) | 193.7 (143.2 to 262.0) |
| Serotype 5 | 62.8 (52.7 to 74.9) | 87.3 (73.2 to 104.2) | 83.5 (64.8 to 107.6) |
| Serotype 6A | 748.7 (576.7 to 972.0) | 1080.9 (880.2 to 1327.4) | 1085.3 (796.9 to 1478.1) |
| Serotype 6B | 727.3 (573.6 to 922.1) | 1159.4 (950.7 to 1413.8) | 1033.3 (754.6 to 1414.8) |
| Serotype 7F | 378.1 (316.4 to 451.9) | 555.4 (466.8 to 660.9) | 345.8 (277.0 to 431.7) |
| Serotype 9V | 550.3 (454.0 to 666.9) | 1085.0 (893.5 to 1317.5) | 723.4 (558.1 to 937.6) |
| Serotype 14 | 391.2 (314.6 to 486.3) | 664.9 (554.1 to 797.9) | 580.5 (433.7 to 777.0) |
| Serotype 18C | 551.9 (445.1 to 684.4) | 845.9 (692.5 to 1033.1) | 621.2 (469.9 to 821.3) |
| Serotype 19A | 238.6 (197.5 to 288.4) | 365.1 (303.0 to 440.0) | 340.6 (264.1 to 439.2) |
| Serotype 19F | 159.0 (131.4 to 192.3) | 242.3 (199.4 to 294.3) | 217.7 (168.1 to 281.8) |
| Serotype 23F | 151.6 (115.3 to 199.3) | 450.2 (357.8 to 566.4) | 292.6 (203.6 to 420.5) |
| Serotype 8 | 211.9 (172.0 to 261.0) | 602.9 (482.9 to 752.8) | 293.8 (220.0 to 392.4) |
| Serotype 10A | 1012.1 (806.7 to 1269.8) | 2005.4 (1586.0 to 2535.7) | 1580.3 (1175.9 to 2123.8) |
| Serotype 11A | 1473.2 (1192.4 to 1820.2) | 1908.2 (1541.5 to 2362.2) | 1566.6 (1140.7 to 2151.4) |
| Serotype 12F | 1054.5 (822.0 to 1352.7) | 1763.4 (1371.8 to 2266.7) | 1401.2 (1001.8 to 1959.7) |
| Serotype 15B | 647.1 (490.8 to 853.1) | 1479.5 (1093.0 to 2002.8) | 1066.9 (721.3 to 1578.1) |
| Serotype 22F | 1772.8 (1354.7 to 2319.8) | 4156.5 (3243.8 to 5326.2) | 2717.8 (1978.4 to 3733.4) |
| Serotype 33F | 2026.2 (1684.3 to 2437.4) | 3174.9 (2579.1 to 3908.3) | 2182.9 (1638.6 to 2907.8) |
OPA GMFR is the ratio of OPA GMTs, 1 month after vaccination to before vaccination. OPA GMFRs from before to 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
| fold rise | Cohort A: 20vPnC | Cohort B: 20vPnC | Cohort C: 20vPnC |
|---|---|---|---|
| Serotype 1 | 2.2 (1.9 to 2.5) | 3.4 (2.9 to 4.1) | 2.0 (1.7 to 2.4) |
| Serotype 3 | 2.4 (2.1 to 2.8) | 3.5 (3.1 to 4.1) | 1.9 (1.6 to 2.3) |
| Serotype 4 | 4.9 (3.9 to 6.1) | 5.0 (4.1 to 6.2) | 2.4 (1.9 to 3.1) |
| Serotype 5 | 2.3 (2.0 to 2.6) | 2.3 (2.0 to 2.6) | 1.8 (1.5 to 2.0) |
| Serotype 6A | 12.6 (9.5 to 16.7) | 8.3 (6.6 to 10.4) | 6.5 (4.7 to 9.1) |
| Serotype 6B | 6.6 (5.2 to 8.4) | 6.7 (5.4 to 8.3) | 4.0 (3.0 to 5.2) |
| Serotype 7F | 2.3 (1.9 to 2.7) | 2.6 (2.2 to 3.0) | 1.6 (1.4 to 2.0) |
| Serotype 9V | 2.4 (2.1 to 2.9) | 3.1 (2.6 to 3.6) | 2.1 (1.7 to 2.6) |
| Serotype 14 | 1.8 (1.5 to 2.1) | 2.3 (1.9 to 2.8) | 1.7 (1.4 to 2.1) |
| Serotype 18C | 3.2 (2.5 to 3.9) | 3.9 (3.2 to 4.8) | 2.2 (1.8 to 2.7) |
| Serotype 19A | 2.9 (2.4 to 3.4) | 2.9 (2.4 to 3.4) | 1.9 (1.6 to 2.2) |
| Serotype 19F | 2.6 (2.2 to 3.1) | 2.7 (2.3 to 3.2) | 1.9 (1.5 to 2.3) |
| Serotype 23F | 6.6 (5.1 to 8.5) | 9.3 (7.4 to 11.8) | 4.5 (3.4 to 6.0) |
| Serotype 8 | 3.6 (2.9 to 4.4) | 22.5 (17.2 to 29.4) | 2.1 (1.6 to 2.8) |
| Serotype 10A | 4.5 (3.5 to 5.7) | 14.4 (10.9 to 19.0) | 4.4 (3.3 to 6.0) |
| Serotype 11A | 2.5 (2.0 to 3.2) | 6.7 (5.0 to 9.0) | 3.1 (2.2 to 4.4) |
| Serotype 12F | 7.2 (5.5 to 9.5) | 31.7 (23.1 to 43.4) | 3.8 (2.7 to 5.5) |
| Serotype 15B | 4.3 (3.3 to 5.7) | 18.9 (13.0 to 27.4) | 4.8 (3.1 to 7.5) |
| Serotype 22F | 11.1 (8.0 to 15.3) | 66.9 (46.5 to 96.4) | 9.8 (6.2 to 15.6) |
| Serotype 33F | 1.8 (1.5 to 2.2) | 5.4 (4.2 to 6.8) | 1.8 (1.4 to 2.2) |
Percentage of participants with a \>=4-fold rise in pneumococcal OPA titers from before vaccination to 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
| percentage of participants | Cohort A: 20vPnC | Cohort B: 20vPnC | Cohort C: 20vPnC |
|---|---|---|---|
| Serotype 1 | 22.9 (17.8 to 28.6) | 40.3 (34.1 to 46.8) | 20.8 (14.0 to 29.2) |
| Serotype 3 | 29.6 (24.0 to 35.8) | 41.3 (35.0 to 47.8) | 18.5 (12.0 to 26.6) |
| Serotype 4 | 41.1 (34.7 to 47.8) | 41.3 (34.9 to 47.9) | 25.2 (17.6 to 34.2) |
| Serotype 5 | 25.7 (20.3 to 31.7) | 27.2 (21.7 to 33.2) | 15.8 (9.8 to 23.6) |
| Serotype 6A | 61.5 (55.0 to 67.7) | 56.4 (49.8 to 62.9) | 44.9 (35.7 to 54.3) |
| Serotype 6B | 53.4 (46.8 to 59.8) | 55.0 (48.5 to 61.5) | 35.3 (26.8 to 44.6) |
| Serotype 7F | 26.2 (20.7 to 32.3) | 30.3 (24.6 to 36.5) | 14.3 (8.5 to 21.9) |
| Serotype 9V | 28.3 (22.5 to 34.7) | 36.0 (29.7 to 42.6) | 20.2 (13.2 to 28.7) |
| Serotype 14 | 15.7 (11.3 to 21.0) | 24.9 (19.5 to 30.9) | 16.0 (9.9 to 23.8) |
| Serotype 18C | 29.4 (23.8 to 35.5) | 38.3 (32.2 to 44.8) | 17.6 (11.3 to 25.7) |
| Serotype 19A | 29.7 (24.0 to 35.9) | 29.3 (23.6 to 35.5) | 15.4 (9.4 to 23.2) |
| Serotype 19F | 29.2 (23.6 to 35.4) | 32.8 (26.9 to 39.1) | 16.9 (10.7 to 25.0) |
| Serotype 23F | 49.6 (43.1 to 56.1) | 58.7 (52.2 to 64.9) | 42.9 (33.8 to 52.3) |
| Serotype 8 | 39.9 (33.4 to 46.7) | 72.6 (66.2 to 78.4) | 30.7 (21.9 to 40.7) |
| Serotype 10A | 45.5 (38.4 to 52.7) | 70.9 (64.0 to 77.1) | 44.0 (34.5 to 53.9) |
| Serotype 11A | 30.4 (23.9 to 37.6) | 54.6 (47.1 to 62.0) | 35.2 (25.4 to 45.9) |
| Serotype 12F | 51.4 (44.4 to 58.4) | 76.5 (70.0 to 82.2) | 40.8 (31.2 to 50.9) |
| Serotype 15B | 37.4 (30.9 to 44.3) | 66.3 (59.0 to 73.1) | 38.4 (28.8 to 48.7) |
| Serotype 22F | 57.0 (50.0 to 63.8) | 83.2 (77.2 to 88.2) | 54.8 (44.7 to 64.6) |
| Serotype 33F | 18.7 (13.6 to 24.8) | 53.6 (46.3 to 60.7) | 19.2 (12.0 to 28.3) |
The percentage of participants with OPA titers \>=LLOQ at 1 month after vaccination were calculated for pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F and 33F.
| percentage of participants | Cohort A: 20vPnC | Cohort B: 20vPnC | Cohort C: 20vPnC |
|---|---|---|---|
| Serotype 1 | 65.4 (59.1 to 71.4) | 87.7 (82.8 to 91.5) | 77.5 (69.0 to 84.6) |
| Serotype 3 | 76.1 (70.3 to 81.3) | 90.5 (86.1 to 93.9) | 87.4 (80.1 to 92.8) |
| Serotype 4 | 76.7 (70.8 to 81.9) | 91.7 (87.5 to 94.9) | 87.1 (79.6 to 92.6) |
| Serotype 5 | 64.8 (58.4 to 70.7) | 74.9 (69.0 to 80.2) | 72.5 (63.6 to 80.3) |
| Serotype 6A | 84.3 (79.1 to 88.6) | 93.8 (89.9 to 96.5) | 90.9 (84.3 to 95.4) |
| Serotype 6B | 86.8 (81.9 to 90.8) | 93.8 (89.9 to 96.5) | 91.7 (85.3 to 96.0) |
| Serotype 7F | 74.2 (68.1 to 79.6) | 84.8 (79.6 to 89.0) | 79.2 (70.8 to 86.0) |
| Serotype 9V | 76.8 (70.9 to 81.9) | 89.5 (84.8 to 93.1) | 85.5 (77.8 to 91.3) |
| Serotype 14 | 85.8 (80.8 to 90.0) | 95.0 (91.5 to 97.4) | 93.3 (87.2 to 97.1) |
| Serotype 18C | 91.8 (87.7 to 94.9) | 96.3 (93.0 to 98.3) | 95.8 (90.5 to 98.6) |
| Serotype 19A | 93.8 (90.0 to 96.5) | 95.9 (92.5 to 98.0) | 98.3 (94.1 to 99.8) |
| Serotype 19F | 71.7 (65.6 to 77.3) | 84.3 (79.1 to 88.6) | 84.7 (77.0 to 90.7) |
| Serotype 23F | 76.3 (70.5 to 81.5) | 93.8 (90.0 to 96.5) | 87.5 (80.2 to 92.8) |
| Serotype 8 | 85.2 (80.0 to 89.5) | 94.7 (90.9 to 97.2) | 90.8 (83.8 to 95.5) |
| Serotype 10A | 92.2 (87.9 to 95.4) | 95.7 (92.0 to 98.0) | 96.4 (91.0 to 99.0) |
| Serotype 11A | 91.2 (86.6 to 94.6) | 94.7 (90.6 to 97.3) | 89.2 (81.5 to 94.5) |
| Serotype 12F | 87.9 (82.9 to 91.9) | 93.0 (88.7 to 96.0) | 91.8 (85.0 to 96.2) |
| Serotype 15B | 84.9 (79.5 to 89.3) | 91.0 (86.2 to 94.6) | 90.0 (82.8 to 94.9) |
| Serotype 22F | 94.0 (90.0 to 96.8) | 99.0 (96.5 to 99.9) | 98.1 (93.5 to 99.8) |
| Serotype 33F | 88.9 (83.9 to 92.7) | 91.8 (87.2 to 95.2) | 87.4 (79.4 to 93.1) |
Collected over Other AEs: local reactions within 10 days after vaccination, systemic events: within 7 days after vaccination (systematic assessment), non serious AEs up to 1 month after Vaccination; SAEs: up to 6 months after vaccination. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort A: 20vPnC | 0/253 (0%) | 2/253 (0.8%) | 173/253 (68.4%) |
| Cohort A: 13vPnC | 0/122 (0%) | 2/122 (1.6%) | 69/122 (56.6%) |
| Cohort B: 20vPnC | 0/246 (0%) | 6/246 (2.4%) | 178/246 (72.4%) |
| Cohort B: PPSV23 | 0/127 (0%) | 2/127 (1.6%) | 96/127 (75.6%) |
| Cohort C: 20vPnC | 0/125 (0%) | 2/125 (1.6%) | 86/125 (68.8%) |
| Event | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC |
|---|---|---|---|---|---|
| CholecystitisHepatobiliary disorders | 0/253 | 1/122 | 0/246 | 0/127 | 0/125 |
| Blood pressure decreasedInvestigations | 0/253 | 1/122 | 0/246 | 0/127 | 0/125 |
| SyncopeNervous system disorders | 0/253 | 0/122 | 2/246 | 0/127 | 0/125 |
| PneumoniaInfections and infestations | 0/253 | 0/122 | 0/246 | 0/127 | 1/125 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/253 | 0/122 | 0/246 | 0/127 | 1/125 |
| DysphagiaGastrointestinal disorders | 0/253 | 0/122 | 0/246 | 1/127 | 0/125 |
| AppendicitisInfections and infestations | 0/253 | 0/122 | 0/246 | 1/127 | 0/125 |
| Clostridium difficile colitisInfections and infestations | 0/253 | 0/122 | 0/246 | 1/127 | 0/125 |
| DehydrationMetabolism and nutrition disorders | 0/253 | 0/122 | 0/246 | 1/127 | 0/125 |
| Acute myocardial infarctionCardiac disorders | 0/253 | 0/122 | 1/246 | 0/127 | 0/125 |
| Event | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC |
|---|---|---|---|---|---|
| Injection site pain (PAIN)General disorders | 127/253 | 52/122 | 150/246 | 71/127 | 66/125 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 81/253 | 38/122 | 83/246 | 58/127 | 47/125 |
| Fatigue (FATIGUE)General disorders | 73/253 | 27/122 | 76/246 | 42/127 | 41/125 |
| Headache (HEADACHE)Nervous system disorders | 45/253 | 22/122 | 33/246 | 27/127 | 24/125 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 17/253 | 13/122 | 29/246 | 20/127 | 21/125 |
| Injection site swelling (SWELLING)General disorders | 25/253 | 8/122 | 23/246 | 18/127 | 5/125 |
| Injection site erythema (REDNESS)General disorders | 20/253 | 3/122 | 21/246 | 16/127 | 6/125 |
| Urinary tract infectionInfections and infestations | 0/253 | 2/122 | 0/246 | 0/127 | 0/125 |
| Pyrexia (FEVER)General disorders | 0/253 | 0/122 | 0/246 | 2/127 | 0/125 |
| DizzinessNervous system disorders | 0/253 | 0/122 | 1/246 | 2/127 | 0/125 |
All randomized population.
| Age, Continuous(years) | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC | Total |
|---|---|---|---|---|---|---|
| Mean | 69.6 ± 3.88 | 70.2 ± 4.09 | 70.7 ± 5.70 | 70.6 ± 5.73 | 70.8 ± 4.26 | 70.3 ± 4.84 |
| Sex: Female, Male(Participants) | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC | Total |
|---|---|---|---|---|---|---|
| Female | 140 | 64 | 140 | 68 | 65 | 477 |
| Male | 113 | 58 | 108 | 59 | 60 | 398 |
| Ethnicity (NIH/OMB)(Participants) | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 3 | 6 | 1 | 2 | 16 |
| Not Hispanic or Latino | 247 | 117 | 233 | 122 | 113 | 832 |
| Unknown or Not Reported | 2 | 2 | 9 | 4 | 10 | 27 |
| Race (NIH/OMB)(Participants) | Cohort A: 20vPnC | Cohort A: 13vPnC | Cohort B: 20vPnC | Cohort B: PPSV23 | Cohort C: 20vPnC | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 1 | 0 | 1 | 0 | 0 | 2 |
| Asian | 1 | 2 | 0 | 2 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 1 | 1 | 1 | 0 | 3 |
| Black or African American | 15 | 8 | 14 | 6 | 4 | 47 |
| White | 236 | 110 | 228 | 118 | 117 | 809 |
| More than one race | 0 | 0 | 1 | 0 | 3 | 4 |
| Unknown or Not Reported | 0 | 1 | 3 | 0 | 1 | 5 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Feb 2019 to primary completion in Feb 2020, 12 months.
Results were first posted in Feb 2021, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 12 months is close to that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine